Quick Answer
Vera Therapeutics, Inc. reported Long-Term Debt of $74.84 million for fiscal year 2025.
Vera Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $74.84M | +47.6% |
| 2024 | $50.69M | +1.6% |
| 2023 | $49.88M | +101.0% |
| 2022 | $24.81M | +404.0% |
| 2021 | $4.92M | — |
| 2020 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.65M | +47.9% | +0.2% |
| June 30, 2025 | $74.46M | +48.1% | +46.3% |
| March 31, 2025 | $50.91M | +1.7% | +0.4% |
| December 31, 2024 | $50.69M | +1.6% | +0.4% |
| September 30, 2024 | $50.47M | +101.5% | +0.4% |
| June 30, 2024 | $50.26M | +101.4% | +0.4% |
| March 31, 2024 | $50.07M | +101.2% | +0.4% |
| December 31, 2023 | $49.88M | +101.0% | +99.2% |
- Vera Therapeutics, Inc. showed an increase of +47.6% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Vera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: